IHC Services, Advanced Tissue Analysis Services, Pharma Drug Trials, AI-Powered Image Analysis, IHC, IF Assay, ISH Assays, Drug Discovery, Translational Research, Clinical Trials, Data Science, Scientific Experts, Pathology, Biology, Image Analysis, Data Science, Artificial Intelligence

Advanced Tissue Analysis Services for Drug Trials

AI-Powered Image Analysis

Intuitive endpoints or advanced Flagship endpoints

IHC / IF / ISH Assays

Discovery, translational research or clinical trials

Data Analysis and Reporting

Typical statistics or data science “deep dives”

Consultation with Scientific Experts

Pathology, biology, image analysis, data science, artificial intelligence

Regulatory Strategy and Support

Strategic regulatory consulting and integrated regulatory submissions support

Our Process

READY TO TAKE THE NEXT STEP?

Flagship carefully tracks our tissue to ensure we can analyze every assay and stay on schedule.

We are trying to bridge from the discovery stage to clinical development. Flagship's pathologists and scientists provide critical input and the company helps us organize and analyze an incredible amount of data. I highly recommend Flagship for its expertise and support for drug development projects.

During clinical trials, I interact with our manufacturing, legal, pre-clinical, and biomarker teams. Our Flagship project manager understands our tight timeline and ensures delivery of the data we need, when we need it.

We are pleased to partner with Flagship Biosciences to integrate their machine learning/AI tools to provide cancer marker detection.

Flagship’s image analysis experts are flexible and willing to work with us to develop projects that meet the changing needs of our clinical trials drug development.

Flagship has a high reputation as a supplier of advanced IHC services and their CAP-CLIA environment is a perfect complement to our own testing facilities.

The ease of leveraging Flagship’s powerful solution is yet another massive differentiator of the company. Clients need not have to change their existing workflows, investments in technology, or even the assays that they use.